OBJECTIVE: To determine the efficacy and safety of commonly prescribed regimens for the treatment of vitamin D insufficiency. METHODS: We performed a retrospective analysis of 306 consecutive patients who were prescribed ergocalciferol (vitamin D2) for correction of vitamin D insufficiency at the Atlanta Veterans Affairs Medical Center between February 2003 and May 2006. Serum levels of parathyroid hormone, 25-hydroxyvitamin D (25-OHD), and calcium were compared before and after treatment with ergocalciferol. Patients who did not have a 25-OHD determination (n = 41) were excluded from analysis. Vitamin D deficiency, insufficiency, and sufficiency were defined as a serum 25-OHD level of <20 ng/mL, 21 to 29 ng/mL, and > or =30 ng/mL, respectively. RESULTS: We identified 36 discrete prescribing regimens. The 3 most common regimens were ergocalciferol 50,000 IU once weekly for 4 weeks followed by 50,000 IU once monthly for 5 months (n = 48); ergocalciferol 50,000 IU once monthly for 6 months (n = 80); and ergocalciferol 50,000 IU 3 times weekly for 6 weeks (n = 27). Each of these 3 treatments significantly increased serum 25-OHD (P<.01), but vitamin D sufficiency was achieved in only 38%, 42%, and 82% of study subjects, respectively. Regimens with >600,000 IU of ergocalciferol given for a mean of 60 +/- 40 days achieved sufficiency in 64% of cases, without vitamin D toxicity. CONCLUSION: In this study, regimens that contained at least 600,000 IU of ergocalciferol appeared to be the most effective in achieving vitamin D sufficiency. Guidelines for the treatment of vitamin D insufficiency in healthy adults should be developed.
OBJECTIVE: To determine the efficacy and safety of commonly prescribed regimens for the treatment of vitamin Dinsufficiency. METHODS: We performed a retrospective analysis of 306 consecutive patients who were prescribed ergocalciferol (vitamin D2) for correction of vitamin Dinsufficiency at the Atlanta Veterans Affairs Medical Center between February 2003 and May 2006. Serum levels of parathyroid hormone, 25-hydroxyvitamin D (25-OHD), and calcium were compared before and after treatment with ergocalciferol. Patients who did not have a 25-OHD determination (n = 41) were excluded from analysis. Vitamin D deficiency, insufficiency, and sufficiency were defined as a serum 25-OHD level of <20 ng/mL, 21 to 29 ng/mL, and > or =30 ng/mL, respectively. RESULTS: We identified 36 discrete prescribing regimens. The 3 most common regimens were ergocalciferol 50,000 IU once weekly for 4 weeks followed by 50,000 IU once monthly for 5 months (n = 48); ergocalciferol 50,000 IU once monthly for 6 months (n = 80); and ergocalciferol 50,000 IU 3 times weekly for 6 weeks (n = 27). Each of these 3 treatments significantly increased serum 25-OHD (P<.01), but vitamin D sufficiency was achieved in only 38%, 42%, and 82% of study subjects, respectively. Regimens with >600,000 IU of ergocalciferol given for a mean of 60 +/- 40 days achieved sufficiency in 64% of cases, without vitamin Dtoxicity. CONCLUSION: In this study, regimens that contained at least 600,000 IU of ergocalciferol appeared to be the most effective in achieving vitamin D sufficiency. Guidelines for the treatment of vitamin Dinsufficiency in healthy adults should be developed.
Authors: Stephen F Hodgson; Nelson B Watts; John P Bilezikian; Bart L Clarke; T Kenney Gray; David W Harris; C Conrad Johnston; Michael Kleerekoper; Robert Lindsay; Marjorie M Luckey; Michael R McClung; Howard R Nankin; Steven M Petak; Robert R Recker Journal: Endocr Pract Date: 2003 Nov-Dec Impact factor: 3.443
Authors: Fiona Wu; Toni Staykova; Anne Horne; Judy Clearwater; Ruth Ames; Barbara Mason; Brandon Orr-Walker; Gregory Gamble; Marilyn Scott; Ian Reid Journal: N Z Med J Date: 2003-08-08
Authors: Heike A Bischoff-Ferrari; Bess Dawson-Hughes; Walter C Willett; Hannes B Staehelin; Marlet G Bazemore; Robert Y Zee; John B Wong Journal: JAMA Date: 2004-04-28 Impact factor: 56.272
Authors: John F Payne; Robin Ray; David G Watson; Cecile Delille; Eva Rimler; Julia Cleveland; Michael J Lynn; Vin Tangpricha; Sunil K Srivastava Journal: Endocr Pract Date: 2012 Mar-Apr Impact factor: 3.443
Authors: B Oliveri; S R Mastaglia; G M Brito; M Seijo; G A Keller; J Somoza; R A Diez; G Di Girolamo Journal: Eur J Clin Nutr Date: 2015-03-18 Impact factor: 4.016
Authors: Nestan Tukvadze; Ekaterina Sanikidze; Maia Kipiani; Gautam Hebbar; Kirk A Easley; Neeta Shenvi; Russell R Kempker; Jennifer K Frediani; Veriko Mirtskhulava; Jessica A Alvarez; Nino Lomtadze; Lamara Vashakidze; Li Hao; Carlos Del Rio; Vin Tangpricha; Henry M Blumberg; Thomas R Ziegler Journal: Am J Clin Nutr Date: 2015-09-23 Impact factor: 7.045
Authors: Albert Shieh; Rene F Chun; Christina Ma; Sten Witzel; Briana Meyer; Brandon Rafison; Leon Swinkels; Tonnie Huijs; Sam Pepkowitz; Brett Holmquist; Martin Hewison; John S Adams Journal: J Clin Endocrinol Metab Date: 2016-05-18 Impact factor: 5.958
Authors: Sara S Oberhelman; Michael E Meekins; Philip R Fischer; Bernard R Lee; Ravinder J Singh; Stephen S Cha; Brian M Gardner; John M Pettifor; Ivana T Croghan; Tom D Thacher Journal: Mayo Clin Proc Date: 2013-12 Impact factor: 7.616